Welcome to our dedicated page for Medipharm Labs news (Ticker: MEDIF), a resource for investors and traders seeking the latest updates and insights on Medipharm Labs stock.
MediPharm Labs Corp (MEDIF) is a leader in pharmaceutical-grade cannabis extraction and precision cannabinoid manufacturing, serving global medical markets through GMP-certified facilities. This page aggregates official news and verified updates about the company’s strategic initiatives, regulatory compliance milestones, and international expansion efforts.
Investors and industry professionals will find timely reports on earnings, partnership announcements, product innovations, and quality control advancements. Our curated collection simplifies tracking MEDIF’s progress in developing non-combustible delivery systems and expanding into regulated markets like Germany and Australia.
All content is sourced from company releases and accredited financial publications to ensure accuracy. Bookmark this page for streamlined access to MEDIF’s latest developments in pharmaceutical cannabis manufacturing, B2B white-label services, and API production.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), a pharmaceutical company specialized in precision-based cannabinoids, has announced the release date for its second quarter 2024 financial results. The results for the period ended June 30, 2024, will be released before markets open on Wednesday, August 14, 2024. The company's executive management team will host a conference call and audio webcast on the same day at 8:30 a.m. Eastern time to discuss the financial results. Participants can join via a North America Toll-Free number or an International Toll number. An audio webcast will also be available, with a replay accessible on the company's website for those unable to attend the live event.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), a pharmaceutical company specializing in precision-based cannabinoids, has announced the release date for its second quarter 2024 financial results. The results for the period ended June 30, 2024, will be released before markets open on Wednesday, August 14, 2024. Following the release, the company's executive management team will host a conference call and audio webcast at 8:30 a.m. (Eastern time) to discuss the financial results. Interested parties can join the call via a North America Toll-Free number or an International Toll number. An audio webcast will also be available, with a replay accessible on the company's website for those unable to participate live.
MediPharm Labs held its annual shareholder meeting on June 26, 2024, with 337 shareholders representing 14.72% of the company's issued shares. All resolutions were passed by a ballot vote.
The election of directors saw Michael Bumby, Chris Halyk, David Pidduck, Shelley Potts, and Chris Taves elected for the upcoming year. Voting results indicated strong support for Chris Halyk (93.15%) and David Pidduck (91.15%).
MNP LLP was appointed as the company's auditor until the next annual meeting, with 97.42% of votes in favor.
MediPharm Labs has secured global manufacturing, distribution, and sales rights for advanced medical cannabis delivery technologies from Remidose Aerosols. This includes metered dose inhalers and aerosol sublingual sprays. The transaction is non-dilutive and based on a performance-driven royalty model. Immediate revenue opportunities arise as MediPharm will take over Remidose's existing sales channels from August 2024, targeting Canadian direct-to-patient platforms and international distributors. MediPharm plans to utilize its GMP infrastructure to expand these products globally. The agreement aligns with MediPharm's strategy to innovate in non-smokable cannabis formats, enhancing its position in the pharmaceutical and wellness-focused sectors.
MediPharm Labs (TSX: LABS, OTCQB: MEDIF, FSE: MLZ) reported significant financial improvements for Q1 2024. Revenue rose by 67% to $9.8M compared to $5.8M in Q1 2023. Gross profit improved to $2.7M or 27% of revenue, up from 6.6% last year. Adjusted EBITDA loss decreased by 70% to $0.9M from $3.1M in Q1 2023. The company has $17M in cash and less than $3M in debt.
MediPharm is optimistic about potential US regulatory changes and plans to leverage its FDA and DEA credentials for future growth. Internationally, they saw a 36% increase in German medical cannabis sales to $1.4M and a 64% rise in Australian sales to $1.8M. CEO David Pidduck highlighted ongoing revenue growth, improved profitability metrics, and strong financial positioning for future investments.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) will release its first quarter financial results for the period ended March 31, 2024, on Wednesday, May 15, 2024. The company specializes in precision-based cannabinoids and will host a conference call to discuss the financial results.
